597514 Disclosed herein is a compound of formula I, specifically 5(-3,4-dichloro-phenyl)-N-2-hydroxy-cycloexyl)-6-(2,2,2-trifluoro-ethoxy)-nicotinamide, preferably (1S, 2R)-I or (1R, 2R)-I. Additionally disclosed is a process for the manufacture thereof comprising coupling a halide intermediate with a boronic acid or boronic acid ester, in the presence of a palladium catalyst under basic conditions. Additionally disclosed is the use thereof in the treatment of diseases which can be treated with ...

- 34 The present application discloses a product comprising (i) as a first component vemurafenib, and (ii) as a second component an MDM2 inhibitor selected from 5 compounds (II) or (III), or a pharmaceutically acceptable salt thereof, for the sequential or concomitant use in the treatment of proliferative diseases, such as cancer, involving b-Raf V600 mutant positive tumor.